Moderna Settles mRNA Patent Dispute with Roivant for Up to $2.25 Billion

The resolution of the patent dispute between Moderna and Roivant Sciences marks a watershed moment in the biotechnology sector, effectively concluding one of the most high-profile legal battles of the post-pandemic era. By agreeing to a settlement of up to $2.25 billion, Moderna has chosen to mitigate the risk of a potentially catastrophic court judgment that could have resulted in even higher damages or ongoing royalty obligations. This move is a strategic pivot for Moderna, which has spent years defending its intellectual property (IP) fortress against claims that it leveraged foundational delivery technology developed by others to bring its COVID-19 vaccine, Spikevax, to market.

At the heart of the litigation was the Lipid Nanoparticle (LNP) delivery system, a critical component that encapsulates mRNA to protect it from degradation and ensure its delivery into human cells. Arbutus Biopharma originally developed the LNP technology and licensed it to Genevant Sciences, a joint venture between Roivant and Arbutus. The plaintiffs argued that Moderna’s vaccine utilized these specific LNP formulations without a proper license. For years, Moderna maintained that its LNP technology was proprietary and distinct, but as the case progressed through the legal system, the risk of a jury trial in a high-stakes venue likely prompted this multi-billion dollar compromise.

“

By agreeing to a settlement of up to $2.25 billion, Moderna has chosen to mitigate the risk of a potentially catastrophic court judgment that could have resulted in even higher damages or ongoing royalty obligations.

For Roivant and Arbutus, the settlement is a transformative financial event. Roivant, known for its 'Vant' model of spinning out biotech subsidiaries, gains a massive non-dilutive cash infusion that strengthens its balance sheet for future drug development and potential acquisitions. For Arbutus, a much smaller player in the space, the settlement validates its foundational IP and provides the capital necessary to advance its own pipeline of hepatitis B and antiviral therapies. The market impact was immediate, with shares of both companies reacting positively to the news of the guaranteed payout and the removal of litigation uncertainty.